- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2020
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2020
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2020 | Daily Highlights
Mycophenolate withdrawal
WITHDRAWAL OF MMF IS SAFE IN QUIESCENT RENAL AND NON-RENAL SLE: RESULTS FROM A MULTI-CENTER RANDOMIZED TRIAL
Abstract: 0989
Authors: E. Chakravarty et al.
Key content:
Mycophenolate Mofetil (MMF) is an important drug for long term treatment of lupus nephritis and other manifestations of SLE. This randomized, unblinded, study compared the risk of SLE flares in patients with quiescent SLE (clinical SLEDAI/cSLEDAI ≤4) treated with long term MMF (≥ 2 years for nephritis; ≥ 1 year for non-nephritis), after MMF withdrawal compared to continued MMF maintenance. The follow-up period was 60 weeks.
Five subjects (10%) in the MMF maintenance arm experienced a clinically significant disease reactivation compared to nine (18%) in the MMF withdrawal arm. The mean time to disease reactivation was 38 weeks (median 46 weeks) in both arms.
Relevance:
This study suggests that the majority of quiescent SLE patients, including those with a history of lupus nephritis, can safely withdraw long-term MMF therapy.
Zusammenfassung und Kommentar von:
Prof. Dr. Ulrich Walker
Basel
